Retatrutide storage is a critical consideration for anyone participating in a clinical trial involving this investigational triple agonist peptide. As a peptide-based injectable targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide shares the same temperature sensitivity as approved agents such as semaglutide and tirzepatide. Because retatrutide has not yet received MHRA or EMA marketing authorisation, there is no publicly available Summary of Product Characteristics — all storage guidance comes from the trial sponsor, site pharmacist, and UK Good Clinical Practice standards. This article outlines the key principles for safe storage, refrigeration, and transport.

How to Store Retatrutide Safely

Retatrutide must be stored according to the IMP label and trial pharmacist's instructions, kept away from light, heat, and freezing, and never shaken or used if the solution appears cloudy or discoloured.

Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. As a peptide-based injectable medicine, it shares many of the same physicochemical vulnerabilities as other agents in its class — such as semaglutide and tirzepatide — meaning that correct storage is essential to preserve its structural integrity and therapeutic efficacy.

Because retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), it is classified as an investigational medicinal product (IMP). All storage and handling requirements are therefore governed by the trial sponsor's Pharmacy Manual or Investigational Medicinal Product Dossier (IMPD), the site pharmacist's instructions, and UK Good Clinical Practice (GCP) standards — not by a publicly available Summary of Product Characteristics (SmPC). The guidance below reflects general principles for peptide injectables; it does not replace the instructions provided by your trial site.

General storage principles for peptide injectables include:

• Follow the IMP label and trial pharmacist's instructions at all times — these are the authoritative source for your specific product and formulation

• Keep away from direct sunlight and UV exposure

• Avoid storing near heat sources such as radiators, ovens, or sunny windowsills

• Do not freeze unless explicitly instructed by the manufacturer or trial pharmacist

• Do not shake or agitate the product — physical agitation can cause peptide aggregation

• Keep in its original packaging to protect from light

• Check the expiry date and batch/lot number before each use and do not use an expired product

• Inspect the solution before each use — do not use if it appears cloudy, discoloured, or contains visible particles; note that visual inspection alone cannot confirm potency

• Keep out of reach of children at all times

• Do not dispose of unused, expired, or potentially compromised product in household waste — quarantine it and return it to the trial pharmacy or site as instructed

References: MHRA Good Clinical Practice guidance; ICH E6(R2) Good Clinical Practice; EU/UK GMP Annex 13 (Investigational Medicinal Products).

Refrigeration Guidelines and Temperature Requirements

Peptide injectables in the same class are stored at 2°C to 8°C in the main body of a refrigerator; the precise conditions for retatrutide are defined by the trial sponsor and have not been publicly confirmed.

For clinical trial participants and healthcare professionals: always follow the storage instructions on the IMP label and those provided by the trial site pharmacist. These instructions supersede any general guidance in this article.

Many peptide-based injectable medicines — including approved GLP-1 receptor agonist therapies such as semaglutide (Ozempic®, Wegovy®) and dulaglutide (Trulicity®) — are stored refrigerated at 2°C to 8°C, as specified in their respective Summaries of Product Characteristics (available on the Electronic Medicines Compendium, emc.medicines.org.uk). Refrigeration at this range slows molecular degradation and helps maintain the peptide's three-dimensional structure, which is critical for receptor binding and pharmacological activity. As a peptide in the same class, retatrutide is likely to have similar requirements, but the precise conditions for this IMP are defined by the sponsor's trial documentation and have not been publicly confirmed at the time of writing.

General refrigeration principles for peptide injectables:

• Store in the main body of the refrigerator, not in the door compartment, where temperatures can fluctuate more significantly

• Do not place directly against the back wall of the refrigerator, as this area may be prone to freezing

• Keep in its original packaging to protect from light

• Do not freeze — freezing can cause irreversible structural damage to the peptide molecule

• Do not shake or agitate the product before or after refrigeration

Some approved peptide injectables permit short-term storage at room temperature once in use (for example, below 25°C or 30°C for a defined number of days), as stated in their SmPCs. Whether similar in-use conditions apply to retatrutide must be confirmed with the prescribing clinician or trial pharmacist, as this is determined by the specific formulation and trial protocol. Do not assume that guidance for approved products applies directly to this IMP.

References: EMC SmPC — Ozempic (semaglutide); EMC SmPC — Wegovy (semaglutide); EMC SmPC — Trulicity (dulaglutide); EU/UK GMP Annex 13.

What Happens If Retatrutide Is Left Unrefrigerated

If retatrutide is left unrefrigerated, quarantine the product immediately, do not re-refrigerate and use it, and contact the trial pharmacist — degraded peptide solutions may still appear clear and colourless.

If retatrutide is inadvertently left outside of refrigeration, the consequences depend on several factors: the ambient temperature, the duration of exposure, and whether the product was in its original sealed packaging or already in use. As a peptide molecule, retatrutide is susceptible to thermal degradation — a process whereby elevated temperatures can accelerate breakdown of the amino acid chain, potentially reducing or eliminating pharmacological activity.

Importantly, degraded peptide solutions may appear visually unchanged — the solution may still look clear and colourless even if the active molecule has been compromised. The safety and efficacy of retatrutide following a storage excursion cannot be assumed; this must be assessed by the trial team using the criteria set out in the trial protocol and site standard operating procedures.

What to do if retatrutide has been left unrefrigerated:

• Do not use the product until you have sought guidance from the trial pharmacist or prescribing clinician

• Quarantine the product — set it aside and do not administer it pending assessment

• Do not attempt to re-refrigerate and use a product that may have been significantly heat-exposed, as returning it to the refrigerator does not reverse degradation

• Contact your trial pharmacist, prescribing clinician, or trial coordinator promptly — they will assess the excursion against the protocol and stability data held by the sponsor

• Document the excursion — record the approximate temperature, duration of exposure, and storage conditions as accurately as possible; this information is required for the clinical team's assessment and may constitute a protocol deviation that must be reported

• Return the product to the trial site if instructed; do not dispose of it in household waste

The safety and efficacy of a product that has been stored outside recommended conditions are unknown. Do not make assumptions about whether a dose is still suitable for use — always defer to the trial team.

References: MHRA GDP/Orange Guide (temperature excursion expectations); EU/UK GMP Annex 13; site SOPs and trial protocol.

Travelling and Transporting Retatrutide

Carry retatrutide in hand luggage in a validated medical-grade cool bag with a temperature logger, and obtain a travel letter from the trial site confirming its status as a clinical trial medicine.

Travelling with an injectable IMP such as retatrutide requires advance planning and written confirmation of requirements from the trial site. Before travelling, always consult your trial coordinator or site pharmacist — specific protocols govern the handling and transport of IMPs, and written authorisation or a travel letter may be required.

The fundamental principle is to maintain the product within its labelled temperature range throughout the journey and to avoid freezing or excessive heat exposure. The trial pharmacy may supply validated transport equipment; use this in preference to commercially sourced alternatives unless the site confirms otherwise.

Practical travel guidance for transporting retatrutide:

• Follow written instructions from the trial pharmacy regarding permitted time out of refrigeration and approved transport equipment

• Use a validated medical-grade cool bag or insulated travel case with a pre-conditioned cool pack — pre-condition ice packs according to the manufacturer's instructions to avoid temperatures below 0°C

• Do not place the product directly on ice or ice packs — use a separator or cloth to prevent freezing

• Use a thermometer or temperature data logger inside the cool bag to monitor conditions during transit; record and report any excursions to the trial site

• When flying, carry the medicine in your hand luggage rather than checked baggage, as cargo holds can reach freezing temperatures

• Carry a letter from your trial site or prescribing clinician confirming the medical necessity of the injectable and its status as a clinical trial medicine; this is particularly important for airport security and customs

• Be aware of destination climate — in hot environments, accommodation may exceed safe storage temperatures; request a refrigerator in advance and confirm its temperature range

• Carry a sharps bin for safe disposal of used needles and devices; check airline and airport rules regarding sharps in hand luggage before travel

• Arrange return of used sharps and any unused or excursion-affected product to the trial site; do not dispose of IMP materials in general waste

References: NHS guidance on travelling with medicines; MHRA GCP guidance; EU/UK GMP Annex 13; airline/CAA general advice on carrying medicines and sharps.

Regulatory Status and Authoritative Sources for Storage Guidance

Retatrutide has no MHRA- or EMA-approved SmPC; storage is governed by the IMP label, the sponsor's Pharmacy Manual, and GCP guidelines, with the trial site pharmacist as the definitive authority.

At the time of writing, retatrutide has not received marketing authorisation from the MHRA or the EMA, and therefore does not have an approved Summary of Product Characteristics (SmPC) or Patient Information Leaflet (PIL) in the UK. It is currently being evaluated in Phase III clinical trials, most notably the TRIUMPH programme conducted by Eli Lilly and Company. As an IMP, its storage and handling are governed by Good Clinical Practice (GCP) guidelines, EU/UK GMP Annex 13 (Investigational Medicinal Products), and the specific trial protocol — not by a publicly available regulatory document.

Within clinical trials conducted in the UK, the handling of IMPs — including storage temperature requirements — is overseen by the trial sponsor, the site pharmacist, and the relevant ethics and regulatory bodies. The MHRA, as the UK's medicines regulator, requires that all IMPs are stored in accordance with the conditions specified in the IMPD and the IMP label. The authoritative sources for retatrutide storage are the IMP label or carton, the sponsor's Pharmacy Manual, and the instructions of the trial site pharmacist. General guidance in this article does not supersede these sources.

Healthcare professionals and trial participants should be aware of the following:

• Always follow the storage instructions on the IMP label and those provided by the trial site pharmacist — these are the definitive reference

• Report any storage deviations (such as accidental freezing or heat exposure) to the trial team promptly; this may constitute a protocol deviation requiring formal documentation and reporting

• Do not source retatrutide outside of an approved clinical trial — it is not currently licensed for use in the UK, and obtaining it through unofficial channels carries significant safety and legal risks

• Consult the MHRA website (www.gov.uk/mhra) for the latest information on the regulatory status of retatrutide in the UK

Once retatrutide receives regulatory approval, an official SmPC will be published, providing definitive storage guidance for both healthcare professionals and patients.

References: UK Statutory Instrument 2004/1031 (as amended) — Medicines for Human Use (Clinical Trials) Regulations; MHRA Good Clinical Practice Guide; EU/UK GMP Annex 13 (Investigational Medicinal Products); ICH E6(R2) Good Clinical Practice; MHRA GDP/Orange Guide.

Frequently Asked Questions